CJC-1295 vs Ipamorelin

CJC-1295 versus Ipamorelin is arguably the most searched comparison in the peptide space, and for good reason. These two compounds are the core building blocks of the most widely used growth hormone peptide stack, yet they work through entirely different biological mechanisms. Understanding how each one operates, why they complement each other, and how they compare to alternatives is essential for anyone evaluating GH peptide protocols.

This guide breaks down the pharmacology, dosing, side effects, and practical considerations for both peptides individually and in combination.

Quick Comparison

• Type: CJC-1295 is a GHRH analog; Ipamorelin is a growth hormone secretagogue (GHRP).
• Mechanism: CJC-1295 activates GHRH receptors on pituitary somatotrophs; Ipamorelin activates ghrelin receptors (GHS-R1a) on pituitary somatotrophs.
• Receptor target: CJC-1295 targets GHRH-R; Ipamorelin targets GHS-R1a.
• Half-life: CJC-1295 approximately 30 minutes without DAC, or 6 to 8 days with DAC; Ipamorelin approximately 2 hours.
• GH release pattern: CJC-1295 produces sustained elevation with preserved pulsatility; Ipamorelin produces a sharp, discrete GH pulse.
• Cortisol effect: Minimal for both — Ipamorelin shows no meaningful cortisol elevation even at doses 200 times the effective GH dose.
• Prolactin effect: Minimal for both.
• Appetite effect: None significant for either.
• Typical dose: CJC-1295 without DAC is 100 mcg one to two times daily; with DAC it is 1 to 2 mg weekly. Ipamorelin is 200 to 300 mcg one to three times daily.

CJC-1295: The GHRH Analog

CJC-1295 is a synthetic 30-amino-acid peptide based on the first 29 residues of human growth hormone-releasing hormone (GHRH 1-29), with four amino acid substitutions at positions 2, 8, 15, and 27. These modifications serve a specific purpose: they protect the molecule from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that breaks down native GHRH within approximately 7 minutes of secretion.

CJC-1295 binds to GHRH receptors on anterior pituitary somatotroph cells, activating the adenylyl cyclase/cAMP/protein kinase A signaling cascade. This drives both growth hormone gene transcription and GH protein release from intracellular storage granules. The result is increased GH secretion that follows the body's existing pulsatile pattern rather than creating a flat, sustained spike.

DAC vs No-DAC: Two Distinct Compounds

CJC-1295 exists in two functionally different forms, and the distinction matters significantly for protocol design.

CJC-1295 with DAC includes a Drug Affinity Complex, a reactive lysine linker that covalently bonds to serum albumin after injection. This albumin binding shields the peptide from degradation and extends its effective half-life to 6 to 8 days. The result is a sustained, continuous elevation of GH signaling that requires only one to two injections per week. However, this continuous stimulation means GH release is more tonically elevated rather than sharply pulsatile.

CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF, retains the four stabilizing amino acid substitutions but omits the albumin-binding complex. Its half-life is approximately 30 minutes, meaning each injection produces a relatively brief amplification of the natural GH pulse before clearing. This shorter duration more closely mimics the body's endogenous pattern of intermittent GHRH signaling.

Ipamorelin: The Selective GHRP

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) first characterized by Novo Nordisk researchers in the late 1990s. It belongs to the growth hormone releasing peptide (GHRP) class but is pharmacologically distinct from older GHRPs in one critical respect: selectivity.

Ipamorelin activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor, on pituitary somatotrophs. This triggers GH release through a calcium-dependent intracellular signaling pathway that is mechanistically independent from the cAMP pathway used by GHRH and its analogs.

What makes Ipamorelin exceptional within its class is what it does not do. The original 1998 characterization study by Raun et al. demonstrated that Ipamorelin did not release ACTH or cortisol at levels significantly different from those observed with GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release. This stands in sharp contrast to GHRP-6 and GHRP-2, which stimulate cortisol, prolactin, and (in the case of GHRP-6) intense hunger alongside their GH-releasing effects.

Ipamorelin's selectivity profile means it raises growth hormone without the hormonal noise that accompanies other secretagogues. No meaningful cortisol elevation. No prolactin spike. No appetite surge. This clean profile is the primary reason it became the preferred GHRP for combination protocols.

Why They Work Better Together

The synergy between GHRH analogs and GHRPs is not theoretical. It is one of the more robustly documented phenomena in growth hormone physiology.

The foundational work by Bowers et al. (1990) demonstrated that submaximal doses of a GHRP combined with GHRH stimulated GH release synergistically, meaning the combined output exceeded the sum of each agent's individual effect. Veldhuis and colleagues expanded on this in subsequent studies, confirming that GHRH and GHRP-2 were "strongly synergistic" in their pituitary effects and that this synergy operated through independent receptor pathways.

The mechanism is straightforward. CJC-1295 (the GHRH analog) binds the GHRH receptor and activates the cAMP/PKA pathway, priming somatotroph cells to synthesize and prepare GH for release. Ipamorelin (the GHRP) binds the GHS-R1a receptor and activates a separate calcium/protein kinase C pathway that triggers the actual secretion of stored GH granules. One prepares the ammunition; the other pulls the trigger.

When both receptors are activated simultaneously, the pituitary produces a GH pulse that is substantially larger than what either signal generates independently. Published data on GHRH/GHRP combinations generally show a 2-fold to 3-fold increase in peak GH over either agent alone at equivalent doses.

Importantly, the Ipamorelin component also suppresses somatostatin tone, the inhibitory signal that opposes GH release. This means the CJC-1295 signal encounters less resistance at the pituitary, further amplifying the combined response.

The CJC-1295 + Ipamorelin Stack Protocol

The following represents the most commonly documented protocol for this combination. All peptide use should be supervised by a qualified medical professional.

Dosing

• CJC-1295 (no DAC / Mod GRF 1-29): 100 mcg per injection
• Ipamorelin: 200 mcg per injection
• Frequency: Once or twice daily. The bedtime dose is the priority injection, as it coincides with the natural nocturnal GH surge. A second injection upon waking is added in twice-daily protocols.

Timing

Timing relative to food intake is important. Elevated blood glucose and insulin blunt pituitary GH release, reducing the effectiveness of both peptides. The optimal windows are:

• Before bed, at least 2 hours after the last meal, particularly one containing carbohydrates
• Upon waking, fasted, at least 30 minutes before eating

Both peptides are administered together as a single subcutaneous injection or as two simultaneous injections. Co-administration is standard practice; there is no benefit to separating the timing.

Cycling

• Standard cycle: 8 to 12 weeks on, followed by 4 weeks off
• Extended cycle: Up to 16 weeks with medical monitoring and mid-cycle bloodwork
• Alternative pattern: 5 days on, 2 days off each week (provides partial receptor recovery)

Cycling prevents GHS-R1a and GHRH-R desensitization, which is the primary mechanism by which continuous peptide use produces diminishing returns. The 4-week break allows receptor populations to resensitize before the next cycle.

Monitoring

Baseline and mid-cycle bloodwork should include IGF-1 levels (the most practical proxy for GH axis activity), fasting glucose and insulin, a complete metabolic panel, and a thyroid panel. Significant IGF-1 elevation above the age-adjusted reference range warrants dose reduction.

Comparison to Other GH Peptide Options

CJC-1295 vs Sermorelin

Both are GHRH analogs targeting the same receptor, but they differ meaningfully in pharmacokinetics. Sermorelin is essentially the unmodified GHRH(1-29) fragment with a half-life of approximately 10 to 20 minutes. CJC-1295 (no DAC) lasts roughly 30 minutes, and the DAC version extends to days. Sermorelin requires more frequent dosing and produces a more transient GH pulse. CJC-1295's modified amino acid backbone confers greater enzymatic resistance and somewhat more sustained receptor activation per injection. Sermorelin does have a longer clinical history, it previously held FDA approval for pediatric GH deficiency, but that approval has been withdrawn.

Ipamorelin vs GHRP-6

Both activate the GHS-R1a receptor, but their selectivity profiles diverge significantly. GHRP-6 produces robust GH release but also drives substantial increases in cortisol, prolactin, and appetite. The appetite stimulation from GHRP-6 is particularly pronounced, a direct consequence of strong ghrelin receptor agonism in the hypothalamus. Ipamorelin achieves comparable GH output without these off-target effects, which is why it largely replaced GHRP-6 in modern stacking protocols.

Ipamorelin vs GHRP-2

GHRP-2 sits between Ipamorelin and GHRP-6 in the selectivity spectrum. It produces a slightly stronger GH pulse than Ipamorelin but also elevates cortisol and prolactin to a modest degree. For users prioritizing maximal GH output and willing to accept some hormonal noise, GHRP-2 remains an option. For clean, side-effect-minimal protocols, Ipamorelin is the standard choice.

CJC-1295 vs Tesamorelin

Tesamorelin is the only GHRH analog with current FDA approval (granted in 2010 for HIV-associated lipodystrophy). It uses an N-terminal trans-3-hexenoic acid modification for DPP-4 resistance, giving it a half-life of approximately 26 to 38 minutes, comparable to CJC-1295 without DAC. Tesamorelin has Phase III randomized controlled trial data, making it the best-characterized GHRH analog from an evidence standpoint. Its primary clinical indication is visceral fat reduction, and it requires daily injection. CJC-1295 lacks equivalent clinical trial data but is more commonly used in combination stacking protocols.

Side Effects and Safety

CJC-1295 Side Effects

In clinical trials, CJC-1295 was described as "safe and relatively well tolerated," with adverse events that were generally mild and transient:

• Injection site reactions (redness, swelling, irritation)
• Facial flushing, particularly within the first 15 to 30 minutes post-injection
• Water retention
• Transient headache (reported in 10% to 15% of trial participants)
• Numbness or tingling at higher doses

No serious adverse events were attributed to CJC-1295 in the published clinical trials. However, those trials were short, the longest involved dosing over 49 days, meaning long-term safety data in humans does not exist.

Ipamorelin Side Effects

Ipamorelin's side effect profile is notably mild. The most commonly reported effects include:

• Injection site irritation
• Mild, transient nausea (primarily during the first week)
• Occasional lightheadedness post-injection
• Headache

The defining safety advantage of Ipamorelin is its selectivity. At therapeutic doses, it does not meaningfully elevate cortisol, prolactin, or ACTH. It does not stimulate appetite. This clean profile persists even at doses far exceeding those needed for GH release.

Combined Stack Safety

When used together, the side effect profile of the stack generally reflects the individual profiles of each component, injection site reactions, occasional flushing, mild water retention. The synergistic GH elevation does mean higher peak GH and IGF-1 levels than either peptide alone, which carries the general cautions associated with sustained GH elevation: potential effects on insulin sensitivity, theoretical concerns regarding existing malignancies, and the importance of monitoring glucose metabolism during extended cycles.

Contraindications for the combined stack include active cancer or high cancer risk (due to IGF-1's growth-promoting properties), uncontrolled diabetes or significant insulin resistance, pregnancy or breastfeeding, and cardiovascular disease requiring active management.

Legal Status

Neither CJC-1295 nor Ipamorelin is approved by the FDA for human therapeutic use. Both are sold as research chemicals and cannot legally be marketed as drugs, dietary supplements, or treatments.

In September 2024, the FDA removed CJC-1295 and Ipamorelin acetate from Category 2 of the interim 503A bulks list and referred them to the Pharmacy Compounding Advisory Committee for formal review. The PCAC subsequently recommended against including these substances in the 503A Bulks Regulation, effectively suspending their availability through compounding pharmacies while evaluation continues. As of March 2026, no formal policy change has restored compounding access, though regulatory discussions remain active.

Both peptides are prohibited under the World Anti-Doping Agency's Prohibited List. CJC-1295 falls under S2.3 as a growth hormone-releasing hormone analog. Ipamorelin is prohibited under S2.4 as a growth hormone secretagogue. Athletes subject to anti-doping testing face sanctions for the use of either compound.

International legality varies by jurisdiction. In many countries, these peptides occupy a gray area, available for research purposes but not approved for clinical use. Users should verify the current regulatory status in their specific jurisdiction.

Conclusion

CJC-1295 and Ipamorelin are complementary rather than competing peptides. CJC-1295 extends the GHRH signal that primes pituitary somatotrophs to produce growth hormone; Ipamorelin activates the ghrelin receptor to trigger its release. Together, they exploit two independent pituitary pathways to produce a synergistic GH pulse that exceeds what either achieves alone, a phenomenon documented across multiple studies of GHRH/GHRP co-administration.

Ipamorelin's clean selectivity profile, no meaningful cortisol, prolactin, or appetite effects, makes it the preferred GHRP for this combination. The no-DAC version of CJC-1295 is the standard pairing partner, as its pulsatile profile complements Ipamorelin's sharp GH pulse better than the sustained elevation produced by the DAC version.

These remain experimental compounds without FDA approval, long-term human safety data, or pharmaceutical-grade quality standards in the research chemical market. Any protocol involving these peptides should be conducted under medical supervision with baseline and on-cycle blood monitoring. The combination is powerful, well-characterized relative to other research peptides, and widely used, but it is not without risks that users must understand and actively manage.